Lupin Ltd.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, raising concerns about the stock's near-term momentum and long-term strength.

Lupin Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lupin Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade from a Buy to a Hold rating, the stock’s long-term performance remains robust, though short-term indicators suggest caution for investors navigating the current market environment.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Despite a modest day change of 0.14%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a reassessment of its near-term outlook.

Lupin Ltd. is currently rated 'Hold' by MarketsMOJO, with this rating last updated on 14 August 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 28 August 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 12.3% surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this increase, the stock underperformed its sector and broader indices, reflecting a complex interplay of market sentiment and technical factors.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable 11.65% surge in open interest (OI) in its derivatives segment, signalling increased market activity and shifting investor positioning. Despite this uptick, the stock underperformed its sector and broader indices, reflecting a complex interplay of market forces and investor sentiment.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Recent technical indicators, including MACD, RSI, and moving averages, reveal a complex picture that investors must carefully analyse amid broader market dynamics.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum gauges, reflecting the stock’s cautious positioning amid broader market fluctuations.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite this positive tilt, the stock’s technical indicators present a nuanced picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, prompting a reassessment of its current market positioning and outlook.

Lupin Ltd., a prominent player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Buy to Hold as of 14 August 2026. This adjustment reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite robust financial performance and attractive valuation metrics, evolving technical indicators and market dynamics have prompted a more cautious stance from analysts.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with bearish signals emerging on weekly and monthly MACD and KST charts, while daily moving averages maintain a mildly bullish outlook. This nuanced technical landscape, coupled with a downgrade in the Mojo Grade from Buy to Hold, suggests investors should carefully reassess their positions amid evolving market dynamics.

Lupin Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 August 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 15 August 2026, providing investors with an up-to-date perspective on the company’s fundamentals and market performance.

Lupin Ltd., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a significant 30.7% surge in open interest in its derivatives segment, even as the stock price declined by 3.8% on 10 Aug 2026. This divergence between rising open interest and falling price signals a complex market positioning that warrants close scrutiny from investors and traders alike.

Lupin Ltd., a prominent mid-cap player in the Pharmaceuticals & Biotechnology sector, witnessed significant trading activity on 10 Aug 2026, with over 24 lakh shares exchanging hands and a total traded value exceeding ₹55,160 lakhs. Despite this high-value turnover, the stock has experienced a notable decline over the past four sessions, underperforming its sector and broader market indices.